Skip to content
Screener

Schering-Plough SGP Free cash flow

Free cash flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$7.3B+157%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$572.8M-38.1%
Glaukos logo
GlaukosGKOS
-$16.49M+19.4%
AbbVie logo
AbbVieABBV
$3.56B+155%
Bausch + Lomb logo
Bausch + LombBLCO
$82M+252%
HRO
HarrowHROW
-$10.25M

Other financials

Income statement

See full
Operating income-$15.4M-108%
Net income-$13.8M-56.6%
EPS (diluted)-$0.69+82.6%

Balance sheet

See full
Cash & equivalents$238.9M+312%
Total debt$1.6M
Total equity$250.1M+463%
Total assets$258.4M

Cash flow

See full
Operating cash flow-$13.5M-65.2%
CapEx$676.0K+312%

Valuation

See full
Market cap$891.05M+6.7%
Enterprise value$653.76M

Returns & leverage

See full
Return on equity-34.3%
Debt / equity
Current ratio38×

Where this comes from

Calculated from Schering-Plough’s reported figures.

The source filing: Schering-Plough’s 10-Q, filed May 14, 2026. Open the filing →

Filed
May 14, 2026, 4:30 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001778922-26-000035

FAQ

What is Schering-Plough's free cash flow?
Schering-Plough (SGP) reported free cash flow of -$14.22M in Q1 2026.
How has Schering-Plough's free cash flow changed year-over-year?
Schering-Plough's free cash flow decreased by 70.0% year-over-year, from -$8.37M to -$14.22M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.

Ask your AI about Schering-Plough's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude